# Anti-programmed Cell Death-1 Ligand 1 (aPDL-1) Antibody Atezolizumab, Bevacizumab and Acetylsalicylic Acid in Recurrent Platinum Resistant Ovarian Cancer

> **NCT02659384** · PHASE2 · COMPLETED · sponsor: **European Organisation for Research and Treatment of Cancer - EORTC** · enrollment: 122 (actual)

## Conditions studied

- Ovarian Neoplasms

## Interventions

- **DRUG:** Bevacizumab
- **DRUG:** atezolizumab
- **DRUG:** acetylsalicylic acid
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT02659384
- **Lead sponsor:** European Organisation for Research and Treatment of Cancer - EORTC
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-12-23
- **Primary completion:** 2021-06
- **Final completion:** 2022-03
- **Target enrollment:** 122 (ACTUAL)
- **Last updated:** 2023-03-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02659384

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02659384, "Anti-programmed Cell Death-1 Ligand 1 (aPDL-1) Antibody Atezolizumab, Bevacizumab and Acetylsalicylic Acid in Recurrent Platinum Resistant Ovarian Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02659384. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*